The norepinephrine transporter (NET) is one of the major targets in neuropsychiatric and neurodegenerative diseases like attention deficit hyperactivity disorder (ADHD), depression, Alzheimer’s disease (AD), Parkinson’s disease (PD) and substance abuse [1]. This evidence concerns the gene SLC6A2 and attention deficit-hyperactivity disorder.